Compare Ascendis Pharma A/S (ASND) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs MGM Resorts International — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while MGM Resorts International trades at $47.25 (market cap $11.99B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MGM | |
|---|---|---|
Market Cap | $17.74B | $11.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $50.69 |
52-Week Low | $163.32 | $30.72 |
Enterprise Value | $18.11B | $41.04B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MGM Resorts International (MGM) trades at $46.88, up 0.95% on the day, with a bullish technical signal and mixed earnings history. The stock shows strong revenue growth from $13.1B in 2022 to $17.5B in 2025, though net income margins have compressed to 1.03%. Recent news highlights potential acquisition talks with Barry Diller at $48.30 per share, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook: MGM offers exposure to gaming and hospitality recovery with a reasonable P/S of 0.71, but high P/E of 64.22 reflects margin pressures. Risks include earnings volatility, debt levels, and regulatory scrutiny. The Diller bid provides near-term upside potential, but execution on profitability remains key for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
